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ABSTRACT
Introduction: adalimumab is a recombinant fully-human mo-
noclonal immunoglobulin (IgG1) antibody utilized in the treatment
of Crohn´s disease. Unfortunately no clinical or genetic markers
exist to predict response to anti-tumor necrosis factor-alpha (TNF)
therapy. The aim of this study was to evaluate the association bet-
ween selected genes involved in cytokine regulation and response
to adalimumab treatment in Crohn’s disease.
Methods: twenty-four patients with Crohn’s disease either
naïve (n = 8) or had lost response or were unable to tolerate the
chimeric anti-TNF antibody infliximab (n=16) were enrolled in the
study. Patients were genotyped for main polymorphisms in
NOD2, CD14 and TLR4 genes. Response to adalimumab treat-
ment was defined as a decrease of Crohn’s disease activity index
of at least 100 points or a closure of at least 50% of fistulas in
case of fistulizing Crohn’s disease.
Results: overall, 75% of patients did respond to treatment.
However, no statistically significant association was found betwe-
en any of the genotypes and the response to adalimumab.
Conclusions: in our small study group no association betwe-
en the studied polymorphisms and response to adalimumab was
apparent. Systematic studies to search for genetic markers of res-
ponse to anti-TNF therapy are necessary.
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INTRODUCTION
Although recent studies have identified several genes
linked to Crohn’s Disease (CD), the discovery of
NOD2/CARD15 gene in 2001 by two independent
groups (1,2) was the first CD susceptibility gene. NOD2
single nucleotide polymorphisms (SNPs) also have been
associated with different clinical forms of the disease in a
number of populations, including some studies in Spain
(3,4). In our country a great heterogeneity among diffe-
rent regions has been described (5), even in a study per-
formed in Asturias not association between NOD2 and
CD was showed (6).
Toll-like receptors (TLRs) play a key role in the recog-
nition of bacteria, virus and other pathogens. Variants of
toll-like receptor-4 (TLR4) and CD14 genes (components
of the lipopolysaccharide receptor complex) may also be
relevant to Crohn’s disease susceptibility, as has been re-
vealed by recent phenotype-genotype TLR-4 and CD14
mutation analyses (7-10).
Adalimumab (ADA) is a recombinant fully-human
monoclonal immunoglobulin (IgG1) antibody utilized in
the treatment of CD, among other inflammatory and im-
mune disorders (11). The mechanism of action of ADA
relies on neutralizing the biological function of tumor ne-
crosis factor (TNFα) by blocking its interaction with
TNF receptors (12). Compared to other treatments of re-
ference such as infliximab, the subcutaneous administra-
tion of ADAoffers patients an advantage by not having to
depend on infusion centers. Additionally, treatment with
ADA is an option on those patients who have lost respon-
se to or are intolerant to infliximab (13-15). According to
clinical trials, this represents a third of the patients under
infliximab during the first year of therapy (16).
No predictive factors of response to ADA have been
identified as yet (17). We hypothesized that mutations in
NOD2, CD14 and TLR4 mutations do not influence response
to adalimumab in patients with Crohn’s disease: a preliminary
report
M. Barreiro-de Acosta1, S. Ouburg2, S. A. Morré2, J. B. A. Crusius2, A. Lorenzo1, J. Potel3,
A. Salvador-Peña2 and J. E. Domínguez-Muñoz1
1Gastroenterology. University Hospital of Santiago de Compostela, Spain. 2Laboratory of Immunogenetics.
Dept. Pathology. VU University Medical Center. Amsterdam, The Netherlands. 3Surgery. University Hospital of Santiago
de Compostela, Spain
1130-0108/2010/102/10/591-595
REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS
Copyright © 2010 ARÁN EDICIONES, S. L.
REV ESP ENFERM DIG (Madrid)
Vol. 102. N.° 10, pp. 591-595, 2010
Recibido: 30-03-10.
Aceptado: 15-04-10.
Correspondencia: Manuel Barreiro-de Acosta. Gastroenterology. Univer-
sity Hospital of Santiago. C/ Choupana, s/n. 15704 Santiago. A Coruña,
Spain. e-mail: manubarreiro@hotmail.com
Barreiro-de Acosta M, Ouburg S, Morré SA, A. Crusius JB, Lo-
renzo A, Potel J, Salvador Peña A, Domínguez-Muñoz JE.
NOD2, CD14 and TLR4 mutations do not influence response
to adalimumab in patients with Crohn’s disease: a preliminary
report. Rev Esp Enferm Dig 2010; 102: 591-595.
CD susceptibility genes might be involved in response to
treatment. ADA suppresses nuclear factor κB (NF-κB) th-
rough the inhibition of TNF-α, whereas NOD2/CARD15
activates NF-κB thus potentially favoring the production of
TNF-α. In this way, NOD2 mutations may be involved in
altered activity of the NF-κB gene which in turn could be
related to differential response to biologic treatment. TLR4
and its transmembrane co-receptor CD14 signaling path-
way results in the activation of NF-κB and triggers pro-in-
flammatory cytokine production.
The objective of the present study is to assess whether
SNPs in NOD2 (R702W, G908R and 1007fs), in TLR4
(Asp299Gly) and in CD14 are predictive factors for dif-
ferential clinical response to treatment with ADA.
METHODS
Twenty-four adult patients with CD attending the
University Hospital of Santiago who had been treated
with ADA were enrolled in the study. Inclusion criteria
were: either naïve to ADA (n = 8) or had lost response
or were unable to tolerate infliximab (n=16). All pa-
tients were stratified on the basis of age, years of disea-
se, gender, and disease evolution according to the Mon-
treal classification (18). From each patient, 15 ml of
venous blood was collected in EDTA tubes. Samples
were kept at -20ºC until DNA extraction. Genotype
analysis for the three main variants of the NOD2 gene
associated with CD: R702W, G908R and 1007fs (also
called SNP8 (dbSNP ID rs2066844), SNP12
(rs2066845) and SNP13 (rs2066847), respectively) as
well as for CD14 (rs2569190) and TLR4 (rs4986790)
was conducted for all patients. Genotyping was perfor-
med by polymerase chain reaction followed by restric-
tion fragment length polymorphism (PCR-RFLP). Fo-
llowing PCR, the amplicons were digested and
products were separated on a 2% (G908R, CD14 -260
and TLR4 896) or 4% (R702W and 1007fs) agarose
gel.
The NOD2 R702W SNPwas assessed using the forward
primer 5’-CGCACAACCTTCAGATCACA-3’, and the re-
verse primer 5’-GGATGGAGTGGAAGTGCTTG-3’. The
PCR product was digested with HpaII (5 h at 37ºC). The
G908R SNP was evaluated utilizing the forward primer 5’-
AAGTCTGTAATGTAAAGCCAC-3’, and the reverse pri-
mer 5’-CCCAGCTCCTCCCTCTTC-3’, and the PCR pro-
duct digested with HhaI (5 h at 37ºC). The 1007fs variant
was assayed according to Crane et al (19). The primers em-
ployed were 5’-GGCAGAAGCCCTCCTGCAGGGCC-3’
(forward) and 5’-CCTCAAAATTCTGCCATTCC-3’
(reverse) and the restriction enzyme used was ApaI (11 h at
30 ºC).The C/T SNP at -260 of the CD14 gene was analyzed
using the forward primer 5’ CCTGCAGA-
ATCCTTCCTGTT-3’ and the reverse primer 5’-
TCACCTCCCCACCTCTCT-3’. The PCR product was di-
gested with HaeIII (5 h at 37ºC) (20). TThe A/G SNP at 896
in the TLR4 gene was analyzed using the forward primer 5’-
AGCATACTTAGACTACCTCCATG-3’ and the reverse
primer 5’-TTACCCTTTCAATAGTCACACTCA-3’ (21).
The PCR product was digested with NcoI.
Response to treatment was assessed at 52 weeks by
two independent gastroenterologists, one being unaware
of the mutation status. Clinical response to ADA treat-
ment in patients with CD was defined as a decrease
from baseline CDAI of at least 100 points. For patients
with fistulizing CD (n = 21), treatment response was de-
fined as closure of at least 50% of the fistulas present at
the beginning of treatment. Loss of response to ADA
was defined as an initial good response followed by a
subsequent reduction in the efficacy of treatment requi-
ring a dosage increase to achieve the maintenance of
clinical response. Adverse events were defined as those
events leading to withdrawal from the study.
Statistical comparisons were conducted using the χ2
test or the Fisher's exact test when appropriate. Statistical
significance was set to p < 0.05. Analyses were carried
out using SPSS 12.0 software v. 12.0 and Epidat software
package.
This study was performed following the ethical princi-
ples of the Declaration of Helsinki for medical research
involving human subjects and was was approved by the
Ethical Committee of Clinic Investigation of Galicia.
RESULTS
Among a group of 165 CD patients, a total of 24 pa-
tients (mean age 40.5 years, mean duration of disease
10 years, female 66.6%) received treatment with ADA.
Eight patients were naïve to ADA, and 16 were intole-
rant to or had lost response to infliximab. A total of
33% of patients had luminal inflammatory CD (Mon-
treal classification B1) and 66% had fistulizing CD
(Montreal classification B3). Clinical data and demo-
graphic characteristics of the population are summari-
zed in table I.
As for treatment response, 75% of patients responded
to ADA, 16.7% lost response to treatment and 12.5% ter-
minated treatment due to adverse events. No differences
in response were observed according to disease evolution
(inflammatory or fistulizing CD), nonetheless a higher
percentage of naïve patients achieved response to treat-
ment in comparison to non-naïve patients.
Six (25%) patients were carriers of at least one of the
three NOD2 mutations. The TLR4 896 allele G was
found in 4.2% of CD patients, whereas the CD14 -260
allele C was present in 62.4% of CD patients.
Response to treatment did not differ between patients
with or without mutations in NOD2 (overall presence or
any of the mutations separately), TLR4 896 and CD14 -
260 (Fig. 1). Additionally, no differences were observed
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with regard to adverse events or lost of response between
patients who were carriers when compared with non-ca-
rriers of any of the studied polymorphisms (Table II).
DISCUSSION
Biological therapies have shown great efficacy in the
treatment of CD particularly in severe cases and in pa-
tients who fail to respond to conventional therapies
such as corticosteroids (22-24). Nonetheless, although
most of the patients have a good response to treatment,
not all patients show a benefit from biological therapies
and some patients are refractory to these novel molecu-
les. Unfortunately, despite several studies of potential
predictors to clinical response, no gene variants predic-
tive of biological therapy response have yet been iden-
tified.
In our study, we aimed to establish an association
between mutations on CARD15, TLR4 and CD14 and
response to ADA treatment. Our rational is based on
the mechanism of action of newer biological therapies,
such as infliximab and adalimumab, which depend on
the suppression of the NF-κB system through inhibi-
tion of TNF-α. Because Nod2 activates NF-κB and po-
tentially interacts with TNF-α production, mutations in
these genes could result in an altered NF-κB activation.
An evaluation at the genetic level could contribute to
reveal the mechanism responsible for the therapeutic
response of biological therapy seen in clinical practice
(25).
Indeed, in rheumatoid arthritis, an association bet-
ween certain genotypes and differential response to
ADA has been reported. As an example, one study has
shown that patients bearing the GGC haplotype of TNF
gene (-238G/-308G/-857C) in a homozygous form sho-
wed low response rate to ADA treatment (26), whereas
in another study, TNF -308 homozygous (G/G) patients
showed better response than heterozygous (G/A) pa-
tients (27). In other studies the development of antibo-
dies directed against adalimumab has been shown to be
associated with interleukin- (IL)10 polymorphisms
(28).
Regarding CD, in previous studies from Leuven
(Belgium) three polymorphisms in apoptosis genes had
been identified potentially influencing the response to
infliximab in luminal and fistulizing CD patients. The
strongest association was seen between the Fas ligand -
843 TT genotype and non-response to infliximab
(29,30). With respect to the genes we studied, two inde-
pendent studies with a large number of patients also ex-
cluded NOD2 gene variants as predictors for response
to infliximab (31,32).
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Table I. Demographic characteristics and clinical data
Patients, n (%)
Total number 24
Gender (Males/Females) 8 (33.3)/16 (66.6)
Smokers (current or ex-smokers) 15 (62.5)
Age
Range 26-58
Mean ± SD 40.5 ± 9.5
Family history of IBD 2 (8.3)
Age at diagnosis
< 40 years (A1) 23 (95.6)
> 40 years (A2) 1 (4.2)
Disease evolution - Phenotype
Inflammatory (B1) 8 (33.3)
Stricturing (B2) 0 (0)
Penetrating (B3) 16 (66.6)
Disease location
Terminal ileum (L1) 9 (37.5)
Colon (L2) 3 (12.5)
Ileum-colon (L3) 12 (50.0)
Upper gastrointestinal tract (L4) 0 (0)
Extraintestinal manifestations 12 (50.0)
IBD: inflammatory bowel disease.
Fig. 1. Percentage of patients carrying mutations in NOD2, TLR4 and
NOD2 who show response to ADA treatment. No statistically signifi-
cant differences of response were observed between genotypes.
Table II. Percentage of patients carrying mutations in NOD2,
TLR4 and CD14 who show loss of response or adverse
reactions
Loss of response Adverse reaction
Yes No p Yes No p
NOD2 25 25 n.s. 0 28 n.s.
TRL4 0 5 n.s. 0 4 n.s.
CD14 75 60 n.s. 62 66 n.s.
Our study supports the results that have been repor-
ted in another study (n=16) which analyzed possible as-
sociations between response to ADA and NOD2 muta-
tions, but in our study in a higher number of patients
(33). Regarding potential influence of mutations in loss
of response or development of adverse events, there are
not specific studies about this setting and will be neces-
sary a higher number of patients to extrapolate conclu-
sions. Moreover, here we show for the first time, with the
limitation of the number of patients, that there is no asso-
ciation between biologic treatment response and TLR4
and CD14 mutations
Nonetheless, the low sample size of our population
and the little number of patients with NOD2 or TLR4
mutations which may be related to the relative homoge-
neity of our population, may limit the extrapolation of
our outcomes. Another limitation is that we also evalua-
ted response and we have no data on remission.
In conclusion, in our Spanish Galician population res-
ponse to ADA was not associated with CD susceptibility
variants in the NOD2, TLR4 and CD14 genes. Subse-
quent studies in a larger and more heterogeneous popula-
tion should be performed.
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